Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
MNMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.70 - $11.02
Previous CloseN/A
Volume779.86K
Average Volume (3M)1.16M
Market Cap
$734.25M
Enterprise Value$412.10M
Total Cash (Recent Filing)$182.99M
Total Debt (Recent Filing)$41.19M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 12, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding76,087,944
10 Day Avg. Volume1,115,917
30 Day Avg. Volume1,164,430
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$26.00Price Target Upside175.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial StrengthMindMed ended with approximately $238M of cash, which is expected to provide cash runway into 2027.
Market LeadershipMindMed has the largest Phase 3 program currently ongoing in psychedelics, with three pivotal trials across two indications with a high degree of comorbidity.
Strategic PositioningBreakthrough Therapy designation granted by the FDA to MM120 in GAD supports the company's strategic position.
Bears Say
Regulatory ChallengesWith functional unblinding a known challenge in the field and expectations high, the quality and robustness of the Phase 3 data will be especially important in determining regulatory path and commercial viability.
Regulatory RisksMM120’s development strategy includes measures intended to mitigate regulatory risks common to psychedelic trials, which may support a potential New Drug Application submission in 2027.
Trial Enrollment RisksThe primary endpoint in both GAD trials is a well-established regulatory benchmark, and the trials are powered at 90% to detect a significant difference versus placebo.
Mind Medicine News
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $4.70 and its highest was $11.02 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $734.25M.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Nov 12, 2025 which is in 59 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Aug 05, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.12.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.5.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 76,087,944 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 2.593%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (175.42% Upside)
$26.00 (175.42% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 818.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.75%
12-Months-Change
Fundamentals
Return on Equity
-59.11%
Trailing 12-Months
Asset Growth
-1.14%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine (MNMD), also known as MindMed, is a biotechnology company focused on developing psychedelic-inspired therapies for the treatment of mental health disorders. The company operates in the biopharmaceutical sector, primarily targeting conditions such as anxiety, depression, addiction, and ADHD through innovative drug development. MindMed's core products and services include research and development of novel psychedelic compounds, clinical trials, and collaborations with healthcare professionals to create effective mental health treatments.
MNMD Company Deck
MNMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for MindMed, driven by strong enrollment in pivotal trials, financial stability, and strategic leadership additions. However, increased R&D expenses present a financial challenge, although they are aligned with the company's growth and trial activities.View all MNMD earnings summariesMNMD Stock 12 Month Forecast
Average Price Target
$26.00
▲(175.42% Upside)
Technical Analysis
Altimmune
―
Sana Biotechnology
―
Verve Therapeutics
―
ATAI Life Sciences
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
2.55% Insiders
5.34% Mutual Funds
27.83% Other Institutional Investors
56.64% Public Companies and Individual Investors